Last reviewed 2026-05-17 · How we verify

Karen Klahr Miller, MD — Portfolio Competitive Intelligence Brief

Karen Klahr Miller, MD pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Portfolio leaders (marketed + Phase 3 / filed)

Therapeutic area mix

• Bone disorders · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

1. Alexion Pharmaceuticals, Inc. · 1 shared drug class
2. Amgen · 1 shared drug class
3. Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
4. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
5. Azienda Ospedaliera Universitaria Integrata Verona · 1 shared drug class
6. Baxalta now part of Shire · 1 shared drug class
7. Bayer · 1 shared drug class
8. AgeneBio · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Karen Klahr Miller, MD:

• Karen Klahr Miller, MD pipeline updates — RSS
• Karen Klahr Miller, MD pipeline updates — Atom
• Karen Klahr Miller, MD pipeline updates — JSON

Cite this brief

Drug Landscape (2026). Karen Klahr Miller, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/karen-klahr-miller-md. Accessed 2026-05-17.

Related

• Karen Klahr Miller, MD full company profile
• All CI briefs
• Build a custom feed